Loading
Laekna, Inc. - B Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Lu Chris Xiangyang, was filed 16 Jul 2026.
Laekna, Inc. - B: what insiders have been doing
Laekna, Inc. - B is a Health Care company. Its directors and officers file their transactions with HKEX. Between 22 October 2025 and 22 October 2026, 3 insiders published 17 filings.
Every open-market trade in the period is a purchase: 11 purchases worth €113k, from 3 insiders, and not a single sale. The totals do not cover 3 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €15k from Lu Chris Xiangyang, disclosed on 16 July 2026, or 0.0043% of market capitalisation. Among those who bought: 3 senior executives.
For context, the typical company on the same exchange (median of 1,314 companies) published 4 filings over the same period, against 17 filings here. Looking back to 2023, when coverage begins, insiders filed 14 purchases and 9 sales.
The clock since the last published purchase (16 July 2026) now reads 100 days. Filings reach the HKEX feed a median of 3 days after the trade. Until a filing is published, the market cannot know about the trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at UCB. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
42
Thresholds
n/a
Buy Volume
€112,626
14 ops. · all time
Sell Volume
€11M
9 ops. · all time
Who traded when
BuySaleLu Chris Xiangyang9 buys3 sales
Gu Xiang-Ju Justin1 buy3 sales
Xie Ling1 buy3 sales
Since the insiders bought
- -3.4%Entry HK$6.42 · Close 21 Oct 2026 HK$6.20
- -25.0%Entry HK$9.04 · Close at T+90 HK$6.78
- -26.1%Entry HK$9.20 · Close at T+90 HK$6.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,344 of 26,280 companies
38.3
score / 100
Value22
Quality55
FCF yld-3.4%
Earn yld-8.3%
EV/EBITDA·
ROE-11%
Gross mgn81%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$6.15
Analyst consensus
3 analysts1.33/5
HK$18.90Target HK$23.36(+280%)HK$27.02
Income statement
RevenueHK$106.7M
Gross profitHK$86.4M81% margin
EBITDA-HK$219.9M-206% margin
Net income-HK$229.3M-39.8% margin
Valuation
PER (forward)-13.6x
P/Book1.9x
Beta-1.19
Balance sheet & cash
Market capHK$2.8B
Total debtHK$120.8M
Free Cash Flow-HK$93.9M
Debt / Equity13%
Profitability & ownership
ROE-10.7%
ROA-7.6%
% insiders23.4%
% institutions18.9%
Last declaration on 11 September 2026
Declarations42 total
375,000 sharesShareXHKGHKEX:DA20260911E00410
375,000 sharesShareXHKGHKEX:DA20260911E00408
375,000 sharesShareXHKGHKEX:DA20260911E00420
18,000 shares@ HK$7.49530.0043% mcap13.4% of flowShareXHKGHKEX:DA20260716E00450
Canonical exit: 13 Oct 2026 (T+90)
18,000 shares@ HK$6.98860.0040% mcap12.5% of flowShareXHKGHKEX:DA20260715E00346
Canonical exit: 12 Oct 2026 (T+90)
17,000 shares@ HK$6.87320.0037% mcap11.6% of flowShareXHKGHKEX:DA20260714E00343
Canonical exit: 11 Oct 2026 (T+90)
17,600 shares@ HK$7.42880.0042% mcap12.9% of flowShareXHKGHKEX:DA20260713E00321
Canonical exit: 8 Oct 2026 (T+90)
17,200 shares@ HK$7.07260.0039% mcap12.1% of flowShareXHKGHKEX:DA20260710E00285
Canonical exit: 7 Oct 2026 (T+90)
17,600 shares@ HK$7.17930.0040% mcap12.5% of flowShareXHKGHKEX:DA20260709E00351
Canonical exit: 6 Oct 2026 (T+90)
16,846 shares@ HK$7.12790.0038% mcap11.9% of flowShareXHKGHKEX:DA20260708E00038
Canonical exit: 5 Oct 2026 (T+90)
17,100 shares@ HK$7.73530.0042% mcap13.1% of flowShareXHKGHKEX:DA20260708E00037
Canonical exit: 1 Oct 2026 (T+90)
2,550,000 sharesShareXHKGHKEX:DA20260608E00579
Canonical exit: 3 Sept 2026 (T+90)
2,550,000 sharesShareXHKGHKEX:DA20260608E00022
Canonical exit: 3 Sept 2026 (T+90)
2,550,000 sharesShareXHKGHKEX:DA20260608E00021
Canonical exit: 3 Sept 2026 (T+90)
400,000 sharesShareXHKGHKEX:DA20260512E00434
400,000 sharesShareXHKGHKEX:DA20260513E00122
400,000 sharesShareXHKGHKEX:DA20260512E00436
375,000 sharesShareXHKGHKEX:DA20250910E00404
375,000 sharesShareXHKGHKEX:DA20250910E00402
375,000 sharesShareXHKGHKEX:DA20250910E00401
900,000 shares@ HK$19.6331.0% of flowShareXHKGHKEX:DA20250625E00431
1,080,000 shares@ HK$20.0337.9% of flowShareXHKGHKEX:DA20250625E00432
840,500 shares@ HK$19.6729.2% of flowShareXHKGHKEX:DA20250625E00430
199,500 sharesShareXHKGHKEX:DA20250619E00399
100,000 sharesShareXHKGHKEX:DA20250619E00401
25 of 42 declarations
About Laekna, Inc. - B
Laekna, Inc. is a company focused on the healthcare and pharmaceutical sector. It is listed on the Hong Kong Stock Exchange (XHKG).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
